AGC Inc. (TSE:5201) entered into an agreement to acquire MolMed S.p.A. (BIT:MLM) from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €240 million on March 16, 2020. As per the offer, AGC Inc. will acquire 463.45 million shares of MolMed S.p.A at an offer price of €0.51 per share. The tender offer is subject to acceptance of a number of shares representing not lower than 66.7% of the entire share capital. The transaction is unanimously approved by the Board of MolMed S.p.A. As of May 29, 2020, CONSOB approved the offer document relating to tender offer. The acceptance period of the offer shall start on June 1, 2020 and shall end on July 24, 2020.

Centerview Partners UK LLP acted as financial advisor and fairness opinion provider to MolMed S.p.A. Cleary Gottlieb represented Centerview Partners as financial advisor to the board of directors of MolMed S.p.A. Nicola Brunetti of Gattai, Minoli, Agostinelli & Partners acted as legal advisor to MolMed S.p.A. Umberto Penco Salvi and Stefano Parrocchetti Piantanida of Clifford Chance Law Office acted as legal advisors to AGC Inc. Luca Fossati, Luca Liistro and Gianfilippo Pezzulo of Chiomenti Studio Legale acted as legal advisors to Finanziaria d'investimento Fininvest S.p.A. Morrow Sodali S.p.A acted as information agent for MolMed. JPMorgan Securities Japan Co., Ltd. acted as financial advisor for AGC Inc.

AGC Inc. (TSE:5201) completed the acquisition of 93.2% in MolMed S.p.A. (BIT:MLM) from Finanziaria d'investimento Fininvest S.p.A. and others for approximately €220 million on July 24, 2020. As per terms, 432.1 million shares have been tendered and the minimum threshold condition is already fulfilled. The consideration will be paid on July 31, 2020. As of July 29, 2020, AGC Inc. has requested the remaining shareholders of MolMed S.p.A. for the compulsory acquisition of remaining stock for €16.25 million. The compulsory acquisition will commence from August 31, 2020 to September 18, 2020. As of September 18, 2020, AGC Inc. has achieved the minimum level of 95% stake. Now, AGC Inc. will go for squeeze out for the remaining stake and will complete the acquisition of 100% stake of MolMed S.p.A. AGC Inc. completed the acquisition of 100% stake in MolMed S.p.A. on September 30, 2020. Upon completion, MolMed's entity name has been changed to AGC Biologics S.p.A.